Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- PHASEIndependent statistical analysis of Effects of Sulforaphane on Normal Prostate Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00946309).
- Phase 1 Trial of Oral Ixabepilone: Complete Statistical AnalysisIndependent statistical analysis of Phase 1 Trial of Oral Ixabepilone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00632424).
- Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00711997).
- Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1): Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1): primary endpoint results, effect estimate with confidence interval,…
- Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00530816).
- Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00285857).
- Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00369681).
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…
- Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I Combination Ixabepilone + Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination Ixabepilone + Cisplatin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00832117).
- Phase I Combination w/ Epirubicin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination w/ Epirubicin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00322374).
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.: Complete Statistical AnalysisIndependent statistical analysis of Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01434602).
- Phase I/II Calcitriol in Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Calcitriol in Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00794547).
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).